JP2024539088A - 腫瘍浸潤ガンマ-デルタt細胞を拡大するための方法及び材料 - Google Patents

腫瘍浸潤ガンマ-デルタt細胞を拡大するための方法及び材料 Download PDF

Info

Publication number
JP2024539088A
JP2024539088A JP2024523401A JP2024523401A JP2024539088A JP 2024539088 A JP2024539088 A JP 2024539088A JP 2024523401 A JP2024523401 A JP 2024523401A JP 2024523401 A JP2024523401 A JP 2024523401A JP 2024539088 A JP2024539088 A JP 2024539088A
Authority
JP
Japan
Prior art keywords
cells
cell population
percent
tcr
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539088A5 (cg-RX-API-DMAC7.html
Inventor
ティー. ロッツェ,マイケル
マーシー,プラナフ
Original Assignee
ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション filed Critical ユニバーシティ オブ ピッツバーグ -オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション
Publication of JP2024539088A publication Critical patent/JP2024539088A/ja
Publication of JP2024539088A5 publication Critical patent/JP2024539088A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2024523401A 2021-10-20 2022-10-14 腫瘍浸潤ガンマ-デルタt細胞を拡大するための方法及び材料 Pending JP2024539088A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257805P 2021-10-20 2021-10-20
US63/257,805 2021-10-20
PCT/US2022/046745 WO2023069322A1 (en) 2021-10-20 2022-10-14 Methods and materials for expanding tumor infiltrating gamma-delta t cells

Publications (2)

Publication Number Publication Date
JP2024539088A true JP2024539088A (ja) 2024-10-28
JP2024539088A5 JP2024539088A5 (cg-RX-API-DMAC7.html) 2025-10-09

Family

ID=85980818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523401A Pending JP2024539088A (ja) 2021-10-20 2022-10-14 腫瘍浸潤ガンマ-デルタt細胞を拡大するための方法及び材料

Country Status (5)

Country Link
US (1) US20230117388A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419118A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539088A (cg-RX-API-DMAC7.html)
CA (1) CA3235971A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023069322A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025082502A1 (en) * 2023-10-18 2025-04-24 Nanjing Legend Biotech Co., Ltd. Pan t cells and methods of manufacturing of the same
ES3034332B2 (es) * 2025-05-21 2026-05-08 Univ Madrid Complutense Método de expansión selectiva in vitro y adquisición de fenotipo residente en tejido decélulas T Yo Vo1+ derivadas de sangre periférica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2336302T3 (es) * 2000-04-03 2010-04-12 Therapure Biopharma Inc. Produccion de celulas ttcr gamma delta.
US9907820B2 (en) * 2013-10-25 2018-03-06 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
RU2756247C2 (ru) * 2014-11-17 2021-09-28 Эдисет Био, Инк. Генетически модифицированные гамма дельта т-клетки
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
WO2018229163A1 (en) * 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
CA3082818A1 (en) * 2017-11-15 2019-05-23 Adicet Bio Inc. Methods for selective expansion of .delta.3 .gamma..delta. t-cell populations and compositions thereof
EP3927353A4 (en) * 2019-02-24 2022-11-23 Gamida-Cell Ltd. METHOD OF ECOTAXY AND RETENTION OF GAMMADELTA T LYMPHOCYTES, OPTIONALLY WITH NATURAL KILLER CELLS, ALLOWING THE GENERATION OF CELLULAR COMPOSITIONS FOR USE IN THERAPY
CA3148588A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Ex vivo gamma delta t cell populations

Also Published As

Publication number Publication date
US20230117388A1 (en) 2023-04-20
WO2023069322A9 (en) 2023-08-10
EP4419118A1 (en) 2024-08-28
EP4419118A4 (en) 2025-04-30
WO2023069322A1 (en) 2023-04-27
CA3235971A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
US11905529B2 (en) Method of enhancing persistence of adoptively infused T cells
JP7698577B2 (ja) 組織常在メモリー様t細胞を生成するための方法及びその使用
JP7584437B2 (ja) 抗bcma car t細胞の製造
Lozano et al. TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity
US20240091259A1 (en) Generation of anti-tumor t cells
US20230117388A1 (en) Methods and materials for expanding tumor infiltrating gamma-delta t cells
Zhang et al. Tumor-specific MHC-II activates CD4+ and CD8+ T cells in head and neck squamous cell carcinoma to boost immunotherapy efficacy
CN112779223B (zh) 偶联嵌合抗原受体细胞及其用途
US20210290672A1 (en) Regulation of tumor-associated t cells
US20250333699A1 (en) Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells
US20250041344A1 (en) Gene editing methods for modulating expression of id-3, an inhibitor of dna-binding transcription factors, thereby affecting t-cell function
US20220325242A1 (en) Idh2 inhibition for producing t-cells and b-cells with a memory phenotype
Kerr Modulation of T Cells to Promote an Anti-Tumor Response: Activation and Inhibition of T Cells for Efficacy in T-Cell Lymphomas and Melanoma
Venkatesh B Cell Leukemia Elicits a Suppressive Tr1-CD4+ T Cell Response That Can Be Reprogrammed With PDL1-Blockade
Snyder cJun Overexpression Sensitizes CAR-T Cells to PD-1 Axis Blockade by Preserving an Intratumoral PD-1⁺ Tcf1⁺ Stem-Like Reservoir
Ho Characterizing the role of the CD58-CD2 axis in anti-cancer immunity
Lebid Activin A Promotes Treg Induction in Cancer Through the Activin Receptor 1C
Zangari Tcf-1 Protects Antitumor TCR-Engineered CD8+ T-Cells from Granzyme-B Mediated Self-Destruction
Melidosian Cancer Cell Antiviral Signaling Amplifies Transcription Output Through Chromatin Alterations To Drive Therapy Resistance
Lan The Role of TCR Engagement Strength in Antitumor CD8 T Cell Exhaustion
Pais Ferreira Developmental origin of central memory CD8+ T cells
WO2026090747A1 (en) Engineered allogeneic cells and uses thereof
Oppermans Identification and Pre-clinical Development of Tumour-Reactive T-cell Receptors from Tumour Infiltrating Lymphocytes
Lupo Generation and genetic engineering of natural killer cells derived from induced pluripotent stem cells for immunotherapy of solid tumors
WO2021060343A1 (ja) Urlc10由来ペプチドまたはdepdc1由来ペプチドを認識するヒトt細胞が発現するt細胞受容体

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251001